ES2735993T3 - Métodos para predecir el resultado clínico del cáncer - Google Patents
Métodos para predecir el resultado clínico del cáncer Download PDFInfo
- Publication number
- ES2735993T3 ES2735993T3 ES10832289T ES10832289T ES2735993T3 ES 2735993 T3 ES2735993 T3 ES 2735993T3 ES 10832289 T ES10832289 T ES 10832289T ES 10832289 T ES10832289 T ES 10832289T ES 2735993 T3 ES2735993 T3 ES 2735993T3
- Authority
- ES
- Spain
- Prior art keywords
- expression
- genes
- gene
- patient
- prognostic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000000034 method Methods 0.000 title claims abstract description 109
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 100
- 201000011510 cancer Diseases 0.000 title claims abstract description 49
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 228
- 230000014509 gene expression Effects 0.000 claims abstract description 168
- 238000004393 prognosis Methods 0.000 claims abstract description 36
- 101000599056 Homo sapiens Interleukin-6 receptor subunit beta Proteins 0.000 claims abstract description 10
- 102100037795 Interleukin-6 receptor subunit beta Human genes 0.000 claims abstract description 10
- 206010006187 Breast cancer Diseases 0.000 claims description 39
- 208000026310 Breast neoplasm Diseases 0.000 claims description 39
- 239000012188 paraffin wax Substances 0.000 claims description 15
- 230000002503 metabolic effect Effects 0.000 claims description 9
- 238000004590 computer program Methods 0.000 claims description 8
- 230000035755 proliferation Effects 0.000 claims description 7
- 230000002596 correlated effect Effects 0.000 abstract description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 82
- 239000000523 sample Substances 0.000 description 76
- 210000001519 tissue Anatomy 0.000 description 39
- 108020004414 DNA Proteins 0.000 description 29
- 238000004458 analytical method Methods 0.000 description 29
- 238000011282 treatment Methods 0.000 description 28
- 108020004999 messenger RNA Proteins 0.000 description 27
- 239000013615 primer Substances 0.000 description 25
- 238000012360 testing method Methods 0.000 description 24
- 102000015694 estrogen receptors Human genes 0.000 description 22
- 108010038795 estrogen receptors Proteins 0.000 description 22
- 238000012545 processing Methods 0.000 description 21
- 230000004083 survival effect Effects 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 16
- 230000000694 effects Effects 0.000 description 16
- 238000004422 calculation algorithm Methods 0.000 description 13
- 238000006243 chemical reaction Methods 0.000 description 13
- 102000040430 polynucleotide Human genes 0.000 description 13
- 108091033319 polynucleotide Proteins 0.000 description 13
- 239000002157 polynucleotide Substances 0.000 description 13
- 206010027476 Metastases Diseases 0.000 description 12
- 230000003321 amplification Effects 0.000 description 12
- 238000013461 design Methods 0.000 description 12
- 239000011159 matrix material Substances 0.000 description 12
- 238000010606 normalization Methods 0.000 description 12
- 238000003199 nucleic acid amplification method Methods 0.000 description 12
- 230000004044 response Effects 0.000 description 12
- 238000003757 reverse transcription PCR Methods 0.000 description 12
- 238000009396 hybridization Methods 0.000 description 11
- 230000009401 metastasis Effects 0.000 description 11
- 230000008569 process Effects 0.000 description 11
- 238000003860 storage Methods 0.000 description 11
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- -1 GSTm 3 Proteins 0.000 description 9
- 238000003556 assay Methods 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 230000000875 corresponding effect Effects 0.000 description 8
- 238000013479 data entry Methods 0.000 description 8
- 238000003745 diagnosis Methods 0.000 description 8
- 238000005259 measurement Methods 0.000 description 8
- 238000002493 microarray Methods 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 239000000090 biomarker Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000002987 primer (paints) Substances 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 7
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 6
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 6
- 239000000975 dye Substances 0.000 description 6
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 238000003364 immunohistochemistry Methods 0.000 description 6
- 238000010837 poor prognosis Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- 108091093088 Amplicon Proteins 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 5
- 101710163270 Nuclease Proteins 0.000 description 5
- 238000004364 calculation method Methods 0.000 description 5
- 230000004186 co-expression Effects 0.000 description 5
- 238000013500 data storage Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 238000011156 evaluation Methods 0.000 description 5
- 210000001165 lymph node Anatomy 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229920001184 polypeptide Polymers 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000010839 reverse transcription Methods 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 108010016281 ADP-Ribosylation Factor 1 Proteins 0.000 description 4
- 102100034341 ADP-ribosylation factor 1 Human genes 0.000 description 4
- 102100031780 Endonuclease Human genes 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 108010006785 Taq Polymerase Proteins 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000007774 longterm Effects 0.000 description 4
- 239000001509 sodium citrate Substances 0.000 description 4
- 238000001356 surgical procedure Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 102100040685 14-3-3 protein zeta/delta Human genes 0.000 description 3
- 102100037513 40S ribosomal protein S23 Human genes 0.000 description 3
- 102100022681 40S ribosomal protein S27 Human genes 0.000 description 3
- 102100022289 60S ribosomal protein L13a Human genes 0.000 description 3
- 102100040623 60S ribosomal protein L41 Human genes 0.000 description 3
- 102100038910 Alpha-enolase Human genes 0.000 description 3
- 102100040356 Angio-associated migratory cell protein Human genes 0.000 description 3
- 108700020472 CDC20 Proteins 0.000 description 3
- 102100031629 COP9 signalosome complex subunit 1 Human genes 0.000 description 3
- 101150023302 Cdc20 gene Proteins 0.000 description 3
- 102100038099 Cell division cycle protein 20 homolog Human genes 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 108010043471 Core Binding Factor Alpha 2 Subunit Proteins 0.000 description 3
- 102100030801 Elongation factor 1-alpha 1 Human genes 0.000 description 3
- 102100036533 Glutathione S-transferase Mu 2 Human genes 0.000 description 3
- 108091059596 H3F3A Proteins 0.000 description 3
- 102100033994 Heterogeneous nuclear ribonucleoproteins C1/C2 Human genes 0.000 description 3
- 102100039236 Histone H3.3 Human genes 0.000 description 3
- 101000964898 Homo sapiens 14-3-3 protein zeta/delta Proteins 0.000 description 3
- 101001097953 Homo sapiens 40S ribosomal protein S23 Proteins 0.000 description 3
- 101000678466 Homo sapiens 40S ribosomal protein S27 Proteins 0.000 description 3
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 description 3
- 101000674326 Homo sapiens 60S ribosomal protein L41 Proteins 0.000 description 3
- 101000882335 Homo sapiens Alpha-enolase Proteins 0.000 description 3
- 101000964180 Homo sapiens Angio-associated migratory cell protein Proteins 0.000 description 3
- 101000940485 Homo sapiens COP9 signalosome complex subunit 1 Proteins 0.000 description 3
- 101000920078 Homo sapiens Elongation factor 1-alpha 1 Proteins 0.000 description 3
- 101001071691 Homo sapiens Glutathione S-transferase Mu 2 Proteins 0.000 description 3
- 101001017574 Homo sapiens Heterogeneous nuclear ribonucleoproteins C1/C2 Proteins 0.000 description 3
- 101000599886 Homo sapiens Isocitrate dehydrogenase [NADP], mitochondrial Proteins 0.000 description 3
- 101001003581 Homo sapiens Lamin-B1 Proteins 0.000 description 3
- 101000772905 Homo sapiens Polyubiquitin-B Proteins 0.000 description 3
- 101001010890 Homo sapiens S-formylglutathione hydrolase Proteins 0.000 description 3
- 101000685323 Homo sapiens Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Proteins 0.000 description 3
- 101000835720 Homo sapiens Transcription elongation factor A protein 1 Proteins 0.000 description 3
- 102100037845 Isocitrate dehydrogenase [NADP], mitochondrial Human genes 0.000 description 3
- 102100026517 Lamin-B1 Human genes 0.000 description 3
- 108700011259 MicroRNAs Proteins 0.000 description 3
- 102100030432 Polyubiquitin-B Human genes 0.000 description 3
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
- 102100025373 Runt-related transcription factor 1 Human genes 0.000 description 3
- 102100029991 S-formylglutathione hydrolase Human genes 0.000 description 3
- 101100010298 Schizosaccharomyces pombe (strain 972 / ATCC 24843) pol2 gene Proteins 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 102100023155 Succinate dehydrogenase [ubiquinone] flavoprotein subunit, mitochondrial Human genes 0.000 description 3
- 102100026430 Transcription elongation factor A protein 1 Human genes 0.000 description 3
- 239000012472 biological sample Substances 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 201000007280 estrogen-receptor negative breast cancer Diseases 0.000 description 3
- VLMZMRDOMOGGFA-WDBKCZKBSA-N festuclavine Chemical compound C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C)=C3C2=CNC3=C1 VLMZMRDOMOGGFA-WDBKCZKBSA-N 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000002679 microRNA Substances 0.000 description 3
- 239000002773 nucleotide Substances 0.000 description 3
- 125000003729 nucleotide group Chemical group 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000003252 repetitive effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000012502 risk assessment Methods 0.000 description 3
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 210000002536 stromal cell Anatomy 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 238000010200 validation analysis Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 2
- 102000004373 Actin-related protein 2 Human genes 0.000 description 2
- 108090000963 Actin-related protein 2 Proteins 0.000 description 2
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 2
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 2
- 241000972773 Aulopiformes Species 0.000 description 2
- 108091011896 CSF1 Proteins 0.000 description 2
- 239000003298 DNA probe Substances 0.000 description 2
- 102100030960 DNA replication licensing factor MCM2 Human genes 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 108700024394 Exon Proteins 0.000 description 2
- 102100032340 G2/mitotic-specific cyclin-B1 Human genes 0.000 description 2
- 101000884385 Homo sapiens Arylamine N-acetyltransferase 1 Proteins 0.000 description 2
- 101000583807 Homo sapiens DNA replication licensing factor MCM2 Proteins 0.000 description 2
- 101001018431 Homo sapiens DNA replication licensing factor MCM7 Proteins 0.000 description 2
- 101001034811 Homo sapiens Eukaryotic translation initiation factor 4 gamma 2 Proteins 0.000 description 2
- 101000868643 Homo sapiens G2/mitotic-specific cyclin-B1 Proteins 0.000 description 2
- 101000946040 Homo sapiens Lysosomal-associated transmembrane protein 4B Proteins 0.000 description 2
- 101000896657 Homo sapiens Mitotic checkpoint serine/threonine-protein kinase BUB1 Proteins 0.000 description 2
- 101000639975 Homo sapiens Sodium-dependent noradrenaline transporter Proteins 0.000 description 2
- 101000653455 Homo sapiens Transcriptional and immune response regulator Proteins 0.000 description 2
- 101000798130 Homo sapiens Tumor necrosis factor receptor superfamily member 11B Proteins 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 102100034726 Lysosomal-associated transmembrane protein 4B Human genes 0.000 description 2
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 2
- 108091027974 Mature messenger RNA Proteins 0.000 description 2
- 102100021691 Mitotic checkpoint serine/threonine-protein kinase BUB1 Human genes 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 238000010802 RNA extraction kit Methods 0.000 description 2
- 108020004682 Single-Stranded DNA Proteins 0.000 description 2
- 102100033929 Sodium-dependent noradrenaline transporter Human genes 0.000 description 2
- 102100030666 Transcriptional and immune response regulator Human genes 0.000 description 2
- 108090000901 Transferrin Proteins 0.000 description 2
- 102000004338 Transferrin Human genes 0.000 description 2
- 102100032236 Tumor necrosis factor receptor superfamily member 11B Human genes 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000009098 adjuvant therapy Methods 0.000 description 2
- 210000000481 breast Anatomy 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960000633 dextran sulfate Drugs 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000011331 genomic analysis Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000009434 installation Methods 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 208000014018 liver neoplasm Diseases 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000010841 mRNA extraction Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000010197 meta-analysis Methods 0.000 description 2
- 238000012775 microarray technology Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 239000013610 patient sample Substances 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 238000000513 principal component analysis Methods 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 235000019515 salmon Nutrition 0.000 description 2
- 238000003196 serial analysis of gene expression Methods 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 239000012581 transferrin Substances 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- 102100022900 Actin, cytoplasmic 1 Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 102000004000 Aurora Kinase A Human genes 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- 102100032311 Aurora kinase A Human genes 0.000 description 1
- 241000713838 Avian myeloblastosis virus Species 0.000 description 1
- 102100021663 Baculoviral IAP repeat-containing protein 5 Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 102100036842 C-C motif chemokine 19 Human genes 0.000 description 1
- 102100025250 C-X-C motif chemokine 14 Human genes 0.000 description 1
- 102100031173 CCN family member 4 Human genes 0.000 description 1
- 102100024155 Cadherin-11 Human genes 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 108010076303 Centromere Protein A Proteins 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 102100038447 Claudin-4 Human genes 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 102100039551 Collagen triple helix repeat-containing protein 1 Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 102100037573 Dual specificity protein phosphatase 12 Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 102100023387 Endoribonuclease Dicer Human genes 0.000 description 1
- 244000148064 Enicostema verticillatum Species 0.000 description 1
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 1
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 1
- 101000933461 Escherichia coli (strain K12) Beta-glucuronidase Proteins 0.000 description 1
- 239000001859 Ethyl hydroxyethyl cellulose Substances 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 102100036528 Glutathione S-transferase Mu 3 Human genes 0.000 description 1
- 102100040896 Growth/differentiation factor 15 Human genes 0.000 description 1
- 102100035688 Guanylate-binding protein 1 Human genes 0.000 description 1
- 102100027421 Heat shock cognate 71 kDa protein Human genes 0.000 description 1
- 102100024501 Histone H3-like centromeric protein A Human genes 0.000 description 1
- 101000798300 Homo sapiens Aurora kinase A Proteins 0.000 description 1
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 description 1
- 101000858068 Homo sapiens C-X-C motif chemokine 14 Proteins 0.000 description 1
- 101000777560 Homo sapiens CCN family member 4 Proteins 0.000 description 1
- 101000762236 Homo sapiens Cadherin-11 Proteins 0.000 description 1
- 101000882890 Homo sapiens Claudin-4 Proteins 0.000 description 1
- 101000746121 Homo sapiens Collagen triple helix repeat-containing protein 1 Proteins 0.000 description 1
- 101001053992 Homo sapiens Deleted in lung and esophageal cancer protein 1 Proteins 0.000 description 1
- 101000924017 Homo sapiens Dual specificity protein phosphatase 1 Proteins 0.000 description 1
- 101000881110 Homo sapiens Dual specificity protein phosphatase 12 Proteins 0.000 description 1
- 101000966403 Homo sapiens Dynein light chain 1, cytoplasmic Proteins 0.000 description 1
- 101000907904 Homo sapiens Endoribonuclease Dicer Proteins 0.000 description 1
- 101001071716 Homo sapiens Glutathione S-transferase Mu 3 Proteins 0.000 description 1
- 101000893549 Homo sapiens Growth/differentiation factor 15 Proteins 0.000 description 1
- 101001001336 Homo sapiens Guanylate-binding protein 1 Proteins 0.000 description 1
- 101001080568 Homo sapiens Heat shock cognate 71 kDa protein Proteins 0.000 description 1
- 101000994375 Homo sapiens Integrin alpha-4 Proteins 0.000 description 1
- 101000598002 Homo sapiens Interferon regulatory factor 1 Proteins 0.000 description 1
- 101000599048 Homo sapiens Interleukin-6 receptor subunit alpha Proteins 0.000 description 1
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 description 1
- 101000711455 Homo sapiens Kinetochore protein Spc25 Proteins 0.000 description 1
- 101000624643 Homo sapiens M-phase inducer phosphatase 3 Proteins 0.000 description 1
- 101001124867 Homo sapiens Peroxiredoxin-1 Proteins 0.000 description 1
- 101000579123 Homo sapiens Phosphoglycerate kinase 1 Proteins 0.000 description 1
- 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 1
- 101001106322 Homo sapiens Rho GTPase-activating protein 7 Proteins 0.000 description 1
- 101000575639 Homo sapiens Ribonucleoside-diphosphate reductase subunit M2 Proteins 0.000 description 1
- 101000617130 Homo sapiens Stromal cell-derived factor 1 Proteins 0.000 description 1
- 101000904152 Homo sapiens Transcription factor E2F1 Proteins 0.000 description 1
- 101000652736 Homo sapiens Transgelin Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102100027004 Inhibin beta A chain Human genes 0.000 description 1
- 229930010555 Inosine Natural products 0.000 description 1
- UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 1
- 102100032818 Integrin alpha-4 Human genes 0.000 description 1
- 102100036981 Interferon regulatory factor 1 Human genes 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102100037792 Interleukin-6 receptor subunit alpha Human genes 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100023330 M-phase inducer phosphatase 3 Human genes 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710154611 Maternal embryonic leucine zipper kinase Proteins 0.000 description 1
- 102100024299 Maternal embryonic leucine zipper kinase Human genes 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 241000713869 Moloney murine leukemia virus Species 0.000 description 1
- 108700019961 Neoplasm Genes Proteins 0.000 description 1
- 102000048850 Neoplasm Genes Human genes 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 238000009004 PCR Kit Methods 0.000 description 1
- KJWZYMMLVHIVSU-IYCNHOCDSA-N PGK1 Chemical compound CCCCC[C@H](O)\C=C\[C@@H]1[C@@H](CCCCCCC(O)=O)C(=O)CC1=O KJWZYMMLVHIVSU-IYCNHOCDSA-N 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102100029139 Peroxiredoxin-1 Human genes 0.000 description 1
- 102100028251 Phosphoglycerate kinase 1 Human genes 0.000 description 1
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
- 102100035194 Placenta growth factor Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102100021446 Rho GTPase-activating protein 7 Human genes 0.000 description 1
- 102100026006 Ribonucleoside-diphosphate reductase subunit M2 Human genes 0.000 description 1
- 108091028664 Ribonucleotide Proteins 0.000 description 1
- 102100023776 Signal peptidase complex subunit 2 Human genes 0.000 description 1
- 108091027967 Small hairpin RNA Proteins 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 108010002687 Survivin Proteins 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102100024026 Transcription factor E2F1 Human genes 0.000 description 1
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 1
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 1
- 102100031013 Transgelin Human genes 0.000 description 1
- 108010020713 Tth polymerase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006593 Urologic Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 241000510009 Varanus griseus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 102000013814 Wnt Human genes 0.000 description 1
- 108050003627 Wnt Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 238000011226 adjuvant chemotherapy Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008887 cellular homeostatic pathway Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 238000010219 correlation analysis Methods 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 238000013523 data management Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 239000005547 deoxyribonucleotide Substances 0.000 description 1
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 239000001177 diphosphate Substances 0.000 description 1
- 235000011180 diphosphates Nutrition 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 201000007281 estrogen-receptor positive breast cancer Diseases 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 108091008039 hormone receptors Proteins 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 108010019691 inhibin beta A subunit Proteins 0.000 description 1
- 229960003786 inosine Drugs 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 230000000394 mitotic effect Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 238000003012 network analysis Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 108091027963 non-coding RNA Proteins 0.000 description 1
- 102000042567 non-coding RNA Human genes 0.000 description 1
- 230000025308 nuclear transport Effects 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000007639 printing Methods 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 238000012340 reverse transcriptase PCR Methods 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000011524 similarity measure Methods 0.000 description 1
- 239000004055 small Interfering RNA Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000011285 therapeutic regimen Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 201000002510 thyroid cancer Diseases 0.000 description 1
- 238000001269 time-of-flight mass spectrometry Methods 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000001393 triammonium citrate Substances 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 239000000107 tumor biomarker Substances 0.000 description 1
- 238000007473 univariate analysis Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
- G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Physics & Mathematics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Bioinformatics & Computational Biology (AREA)
- Theoretical Computer Science (AREA)
- Medical Informatics (AREA)
- Evolutionary Biology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US26376309P | 2009-11-23 | 2009-11-23 | |
| PCT/US2010/057490 WO2011063274A2 (en) | 2009-11-23 | 2010-11-19 | Methods to predict clinical outcome of cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2735993T3 true ES2735993T3 (es) | 2019-12-23 |
Family
ID=44060376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES10832289T Active ES2735993T3 (es) | 2009-11-23 | 2010-11-19 | Métodos para predecir el resultado clínico del cáncer |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20110123990A1 (enExample) |
| EP (4) | EP4350001A3 (enExample) |
| JP (7) | JP5964752B2 (enExample) |
| AU (1) | AU2010321829B2 (enExample) |
| CA (2) | CA2776751C (enExample) |
| DK (1) | DK2504451T3 (enExample) |
| ES (1) | ES2735993T3 (enExample) |
| HU (1) | HUE044374T2 (enExample) |
| IL (5) | IL219051A (enExample) |
| MX (3) | MX391499B (enExample) |
| NZ (1) | NZ599194A (enExample) |
| PL (1) | PL2504451T3 (enExample) |
| WO (1) | WO2011063274A2 (enExample) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| CA2848463A1 (en) | 2004-04-09 | 2005-10-27 | Genomic Health, Inc. | Gene expression markers for predicting response to chemotherapy |
| CA3061785A1 (en) * | 2004-11-05 | 2006-05-18 | Genomic Health, Inc. | Predicting response to chemotherapy using gene expression markers |
| WO2007123772A2 (en) | 2006-03-31 | 2007-11-01 | Genomic Health, Inc. | Genes involved in estrogen metabolism |
| RU2011102743A (ru) * | 2008-06-26 | 2012-08-10 | Дана-Фарбер Кэнсер Инститьют, Инк. (Us) | Характерные признаки и детерминанты, связанные с метастазированием, и способы их применения |
| US20120041274A1 (en) | 2010-01-07 | 2012-02-16 | Myriad Genetics, Incorporated | Cancer biomarkers |
| DK177532B1 (en) | 2009-09-17 | 2013-09-08 | Bio Bedst Aps | Medical use of sPLA2 hydrolysable liposomes |
| WO2011063274A2 (en) * | 2009-11-23 | 2011-05-26 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
| CA3256492A1 (en) | 2010-01-11 | 2025-11-29 | Genomic Health Inc | Method to use gene expression to determine likelihood of clinical outcome of renal cancer |
| GB201009798D0 (en) | 2010-06-11 | 2010-07-21 | Immunovia Ab | Method,array and use thereof |
| EP3812469A1 (en) | 2010-07-07 | 2021-04-28 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| MX338883B (es) | 2010-07-27 | 2016-05-04 | Genomic Health Inc | Metodo para usar expresion de gen para determinar el pronostico de cancer de prostata. |
| WO2012030840A2 (en) | 2010-08-30 | 2012-03-08 | Myriad Genetics, Inc. | Gene signatures for cancer diagnosis and prognosis |
| US8361720B2 (en) | 2010-11-15 | 2013-01-29 | Exact Sciences Corporation | Real time cleavage assay |
| US8916344B2 (en) | 2010-11-15 | 2014-12-23 | Exact Sciences Corporation | Methylation assay |
| WO2012135008A1 (en) * | 2011-03-26 | 2012-10-04 | Oregon Health And Science University | Gene expression predictors of cancer prognosis |
| CA2840472A1 (en) * | 2011-06-22 | 2012-12-27 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of bladder cancer |
| US20140302042A1 (en) * | 2011-07-01 | 2014-10-09 | Dana-Farber Cancer Institute, Inc. | Methods of predicting prognosis in cancer |
| US10559048B2 (en) * | 2011-07-13 | 2020-02-11 | The Multiple Myeloma Research Foundation, Inc. | Methods for data collection and distribution |
| CA2844805A1 (en) * | 2011-08-16 | 2013-02-21 | Oncocyte Corporation | Methods and compositions for the treatment and diagnosis of breast cancer |
| EP2776830B1 (en) * | 2011-11-08 | 2018-05-09 | Genomic Health, Inc. | Method of predicting breast cancer prognosis |
| JP5805518B2 (ja) * | 2011-12-21 | 2015-11-04 | 株式会社島津製作所 | マルチプレックス大腸がんマーカーパネル |
| SG11201404390WA (en) | 2012-01-31 | 2014-08-28 | Genomic Health Inc | Gene expression profile algorithm and test for determining prognosis of prostate cancer |
| GB201206323D0 (en) * | 2012-04-10 | 2012-05-23 | Immunovia Ab | Methods and arrays for use in the same |
| CA2871076A1 (en) * | 2012-04-20 | 2013-10-24 | Memorial Sloan-Kettering Cancer Center | Gene expression profiles associated with metastatic breast cancer |
| US20150299799A1 (en) | 2012-10-05 | 2015-10-22 | Michael Sturzl | Method for Detecting an Increased Risk or Incidence of Colorectal Cancer |
| WO2014078700A1 (en) | 2012-11-16 | 2014-05-22 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| KR101672531B1 (ko) * | 2013-04-18 | 2016-11-17 | 주식회사 젠큐릭스 | 조기 유방암 예후 예측 진단용 유전자 마커 및 이의 용도 |
| ES2829415T3 (es) * | 2013-05-30 | 2021-05-31 | Genomic Health Inc | Algoritmo de perfil de expresión génica para calcular una puntuación de recurrencia para un paciente con cáncer de riñón |
| WO2014195032A1 (en) * | 2013-06-07 | 2014-12-11 | Medical Prognosis Institute A/S | Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients |
| WO2015138769A1 (en) * | 2014-03-12 | 2015-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for assessing patients with non-small cell lung cancer |
| EP3143160B1 (en) | 2014-05-13 | 2019-11-06 | Myriad Genetics, Inc. | Gene signatures for cancer prognosis |
| US10184154B2 (en) | 2014-09-26 | 2019-01-22 | Mayo Foundation For Medical Education And Research | Detecting cholangiocarcinoma |
| FI3198035T3 (fi) | 2014-09-26 | 2023-01-31 | Menetelmiä lääkevasteen ennustamiseksi | |
| WO2016092299A1 (en) * | 2014-12-09 | 2016-06-16 | Medical Research Council | Methods and kits for predicting the response to therapy of cancer |
| CN107532124B (zh) | 2015-03-27 | 2022-08-09 | 精密科学公司 | 检测食管疾病 |
| CN108350485A (zh) | 2015-10-30 | 2018-07-31 | 精密科学发展有限责任公司 | 血浆dna的多重扩增检测测定以及分离和检测 |
| US11401558B2 (en) | 2015-12-18 | 2022-08-02 | Clear Gene, Inc. | Methods, compositions, kits and devices for rapid analysis of biological markers |
| CN110225984A (zh) * | 2016-09-07 | 2019-09-10 | 科技研究局 | 鉴别癌症风险的方法和治疗选择 |
| US9725769B1 (en) | 2016-10-07 | 2017-08-08 | Oncology Venture ApS | Methods for predicting drug responsiveness in cancer patients |
| AU2017258901A1 (en) | 2016-12-30 | 2018-07-19 | Allarity Therapeutics Europe ApS | Methods for predicting drug responsiveness in cancer patients |
| CN110475875B (zh) | 2017-01-27 | 2024-06-25 | 精密科学公司 | 通过分析甲基化dna检测结肠瘤形成 |
| WO2018212192A1 (ja) * | 2017-05-18 | 2018-11-22 | 京都府公立大学法人 | 癌の予後及び／又は転移可能性を評価する方法及びマーカー |
| US12275994B2 (en) * | 2017-06-22 | 2025-04-15 | Clear Gene, Inc. | Methods and compositions for the analysis of cancer biomarkers |
| MX389484B (es) | 2017-11-13 | 2025-03-20 | The Multiple Myeloma Res Foundation Inc | Base de datos, de datos moleculares, omicos, de inmunoterapia, metabolicos, epigeneticos y clinicos, integrados |
| US10648025B2 (en) | 2017-12-13 | 2020-05-12 | Exact Sciences Development Company, Llc | Multiplex amplification detection assay II |
| WO2019173647A1 (en) * | 2018-03-08 | 2019-09-12 | University Of Notre Dame Du Lac | Products for assessing colorectal cancer molecular subtype and risk of recurrence and for determining and adminstering treatment protocols based thereon |
| JP7199045B2 (ja) * | 2018-04-13 | 2023-01-05 | 国立大学法人大阪大学 | 乳癌の予後に関する情報の取得方法、乳癌の予後の判定装置及びコンピュータプログラム |
| JP7444376B2 (ja) * | 2018-09-21 | 2024-03-06 | 国立大学法人 東京大学 | がんの予後判定方法 |
| JP2019032334A (ja) * | 2018-10-03 | 2019-02-28 | イムノヴィア・アクチエボラーグ | 乳癌関連の疾患状態を決定する方法およびこの方法における使用のためのアレイ |
| KR102216645B1 (ko) * | 2018-10-29 | 2021-02-17 | 사회복지법인 삼성생명공익재단 | 폐암의 분자 아형 결정을 위한 바이오마커 패널 및 이의 용도 |
| US20220033912A1 (en) * | 2018-12-08 | 2022-02-03 | Pfs Genomics Inc | Transcriptomic profiling for prognosis of breast cancer to identify subjects who may be spared adjuvant systemic therapy |
| CN113785076B (zh) * | 2019-05-03 | 2024-06-11 | 株式会社递希真 | 预测癌症预后的方法及其组合物 |
| CN111235270B (zh) * | 2019-08-29 | 2022-04-29 | 北京臻知医学科技有限责任公司 | 一种基于高通量测序法的肿瘤抗原表达检测引物及试剂盒 |
| US12165747B2 (en) * | 2020-01-23 | 2024-12-10 | The Broad Institute, Inc. | Molecular spatial mapping of metastatic tumor microenvironment |
| WO2022174089A1 (en) * | 2021-02-12 | 2022-08-18 | Mammogen, Inc. | Biomarkers for the diagnosis of breast cancer |
| US20220285032A1 (en) * | 2021-03-08 | 2022-09-08 | Castle Biosciences, Inc. | Determining Prognosis and Treatment based on Clinical-Pathologic Factors and Continuous Multigene-Expression Profile Scores |
| CN117116345B (zh) * | 2023-07-24 | 2025-09-16 | 中国人民解放军军事科学院军事医学研究院 | 一种基于基因调控网络构建患者生存网络的方法 |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7171311B2 (en) * | 2001-06-18 | 2007-01-30 | Rosetta Inpharmatics Llc | Methods of assigning treatment to breast cancer patients |
| DK1410011T3 (da) * | 2001-06-18 | 2011-07-18 | Netherlands Cancer Inst | Diagnose og prognose for brystcancerpatienter |
| US7705120B2 (en) * | 2001-06-21 | 2010-04-27 | Millennium Pharmaceuticals, Inc. | Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer |
| EP2261368A1 (en) * | 2002-03-13 | 2010-12-15 | Genomic Health, Inc. | Gene expression profiling in biopsied tumor tissues |
| US20040067234A1 (en) * | 2002-07-11 | 2004-04-08 | Paz Einat | Isocitrate dehydrogenase and uses thereof |
| US20040231909A1 (en) * | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| EP1644858B1 (en) * | 2003-07-10 | 2017-12-06 | Genomic Health, Inc. | Expression profile algorithm and test for cancer prognosis |
| EP1730308A4 (en) * | 2004-03-05 | 2008-10-08 | Rosetta Inpharmatics Llc | CLASSIFICATION OF BREAST CANCER PATIENTS USING A COMBINATION OF CLINICAL CRITERIA AND INFORMATIVE SKILLS |
| WO2006037485A2 (en) * | 2004-09-30 | 2006-04-13 | Bayer Healthcare Ag | Methods and kits for the prediction of therapeutic success and recurrence free survival in cancer therapy |
| JP2008534002A (ja) * | 2005-04-01 | 2008-08-28 | エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド | 乳癌の分類に関する材料および方法 |
| WO2006133460A2 (en) * | 2005-06-09 | 2006-12-14 | Yale University | Methods for diagnosing and treating breast cancer based on a her/er ratio |
| US20070099209A1 (en) * | 2005-06-13 | 2007-05-03 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| WO2006138275A2 (en) * | 2005-06-13 | 2006-12-28 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| TWI304443B (en) * | 2005-12-30 | 2008-12-21 | Nat Health Research Institutes | Alpha-enolase specific antibody and method of use |
| WO2007123772A2 (en) * | 2006-03-31 | 2007-11-01 | Genomic Health, Inc. | Genes involved in estrogen metabolism |
| JP2010524456A (ja) * | 2007-04-16 | 2010-07-22 | イプソゲン | 乳癌に罹患している雌哺乳動物に対する臨床転帰の傾向を評価する方法 |
| WO2008150512A2 (en) * | 2007-06-04 | 2008-12-11 | University Of Louisville Research Foundation, Inc. | Methods for identifying an increased likelihood of recurrence of breast cancer |
| WO2009095319A1 (en) * | 2008-01-28 | 2009-08-06 | Siemens Healthcare Diagnostics Gmbh | Cancer prognosis by majority voting |
| WO2009132928A2 (en) * | 2008-05-02 | 2009-11-05 | Siemens Healthcare Diagnostics Gmbh | Molecular markers for cancer prognosis |
| EP2641978A1 (en) * | 2008-05-12 | 2013-09-25 | Genomic Health, Inc. | Tests to predict responsiveness of cancer patients to chemotherapy treatment options |
| WO2011063274A2 (en) * | 2009-11-23 | 2011-05-26 | Genomic Health, Inc. | Methods to predict clinical outcome of cancer |
-
2010
- 2010-11-19 WO PCT/US2010/057490 patent/WO2011063274A2/en not_active Ceased
- 2010-11-19 MX MX2019003811A patent/MX391499B/es unknown
- 2010-11-19 NZ NZ599194A patent/NZ599194A/en unknown
- 2010-11-19 AU AU2010321829A patent/AU2010321829B2/en active Active
- 2010-11-19 EP EP23213439.5A patent/EP4350001A3/en active Pending
- 2010-11-19 MX MX2016003089A patent/MX363817B/es unknown
- 2010-11-19 ES ES10832289T patent/ES2735993T3/es active Active
- 2010-11-19 CA CA2776751A patent/CA2776751C/en active Active
- 2010-11-19 CA CA3043089A patent/CA3043089A1/en not_active Withdrawn
- 2010-11-19 EP EP19175741.8A patent/EP3556867A1/en not_active Withdrawn
- 2010-11-19 JP JP2012540103A patent/JP5964752B2/ja active Active
- 2010-11-19 EP EP20177718.2A patent/EP3739060A1/en not_active Withdrawn
- 2010-11-19 PL PL10832289T patent/PL2504451T3/pl unknown
- 2010-11-19 DK DK10832289.2T patent/DK2504451T3/da active
- 2010-11-19 EP EP10832289.2A patent/EP2504451B1/en active Active
- 2010-11-19 HU HUE10832289 patent/HUE044374T2/hu unknown
- 2010-11-19 MX MX2012005822A patent/MX337650B/es active IP Right Grant
- 2010-11-19 US US12/950,732 patent/US20110123990A1/en not_active Abandoned
-
2012
- 2012-04-04 IL IL219051A patent/IL219051A/en active IP Right Grant
-
2016
- 2016-06-30 JP JP2016129697A patent/JP2016214245A/ja active Pending
- 2016-11-23 IL IL249159A patent/IL249159A0/en unknown
-
2017
- 2017-02-03 US US15/423,977 patent/US20170211154A1/en not_active Abandoned
-
2018
- 2018-01-21 IL IL257063A patent/IL257063B/en active IP Right Grant
- 2018-08-02 JP JP2018145578A patent/JP7042717B2/ja active Active
-
2019
- 2019-01-03 IL IL264072A patent/IL264072B/en active IP Right Grant
- 2019-01-09 US US16/243,207 patent/US20190241967A1/en not_active Abandoned
-
2020
- 2020-08-04 IL IL276487A patent/IL276487B/en unknown
- 2020-09-11 US US17/018,143 patent/US20210062275A1/en not_active Abandoned
- 2020-12-28 JP JP2020218527A patent/JP2021058207A/ja active Pending
-
2022
- 2022-08-02 JP JP2022123265A patent/JP2022166064A/ja active Pending
- 2022-08-16 JP JP2022129605A patent/JP2022169647A/ja active Pending
-
2023
- 2023-12-18 JP JP2023213416A patent/JP2024037948A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2735993T3 (es) | Métodos para predecir el resultado clínico del cáncer | |
| JP6246845B2 (ja) | 遺伝子発現を用いた前立腺癌の予後を定量化する方法 | |
| ES3027507T3 (en) | Method to use gene expression to determine likelihood of clinical outcome of renal cancer | |
| JP6351112B2 (ja) | 前立腺癌の予後を定量化するための遺伝子発現プロフィールアルゴリズムおよび試験 | |
| EP2425020A1 (en) | Gene expression profile algorithm and test for likelihood of recurrence of colorectal cancer and response to chemotherapy | |
| JP2016521979A (ja) | 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム | |
| ES2914727T3 (es) | Algoritmos y métodos para evaluar los criterios clínicos tardíos en el cáncer de próstata | |
| WO2015066068A1 (en) | Methods of incorporation of transcript chromosomal locus information for identification of biomarkers of disease recurrence risk | |
| AU2017268510A1 (en) | Method for using gene expression to determine prognosis of prostate cancer | |
| WO2013130465A2 (en) | Gene expression markers for prediction of efficacy of platinum-based chemotherapy drugs | |
| WO2014130617A1 (en) | Method of predicting breast cancer prognosis | |
| WO2014130444A1 (en) | Method of predicting breast cancer prognosis | |
| US20110287958A1 (en) | Method for Using Gene Expression to Determine Colorectal Tumor Stage | |
| HK40014990A (en) | Methods to predict clinical outcome of cancer | |
| HK40011641B (en) | Algorithms and methods for assessing late clinical endpoints in prostate cancer |